QUESTIONSSafety Neuropharmacology
Venue: Melrose Hotel
Location: Washington, District Of Columbia, United States
| Event Date/Time: Apr 11, 2005 | End Date/Time: Apr 12, 2005 |
Report as SpamDescription
The current climate surrounding pharmaceutical development is lending itself to increased pressures on industry regarding the early safety assessment of drugs. As a result, preclinical toxicity screening methods for adverse cardiovascular, renal, hepatic, immunological and age-dependant effects have been receiving a lot of attention recently. However, testing guidelines and regulatory requirements can be vague, and somewhat lacking, as is evident in the case of neurotoxicity assessment.
ICH S7A clearly suggests testing all drugs for neurotoxic effects without suggesting specific testing methods. Undoubtedly, the value of preclinical neurotoxicity screens relies on their ability to properly identify and predict adverse effects on the nervous system. Thus there is a growing need for universally accepted and well-validated assessment tools that can describe neurotoxic effects using histological, behavioral and molecular techniques.
The objective of the Safety Neuropharmacology meeting is to bring together experts from a variety of disciplines to review the conventional methods of neurotoxicity assessment, while incorporating new methodology for a current discussion of how best to evaluate neurotoxic effects in pharmaceutical development. Delegates will hear practical presentations on:
DEFINING ICH S7A FOR CNS SAFETY PHARMACOLOGY BEYOND THE FOB
DESIGNING, CONDUCTING, ANALYZING AND INTERPRETING COST-EFFECTIVE CNS SAFETY PHARMACOLOGY STUDY PROGRAMS
ENSURING GLP IN NEUROBEHAVIORAL TESTING
THE EUROPEAN REGULATORY PERSPECTIVE ON CNS SAFETY PHARMACOLOGY SCREENING
THE USE OF AUTOMATED SYSTEMS FOR COMPLEX BEHAVIORAL ANALYSES
EVALUATING THE POTENTIAL FOR DRUG ABUSE OR DEPENDENCE
...among many others from regulatory, academic and industry leaders in the field.
Take advantage of this remarkable opportunity to be part of the first Safety Neuropharmacology meeting! Register early to reserve your spot! Call 800-686-2276 or register online at www.pharmedassociates.com. Please join me in Washington, DC on April 11th & 12th 2005 for this one-of-a-kind meeting.
ICH S7A clearly suggests testing all drugs for neurotoxic effects without suggesting specific testing methods. Undoubtedly, the value of preclinical neurotoxicity screens relies on their ability to properly identify and predict adverse effects on the nervous system. Thus there is a growing need for universally accepted and well-validated assessment tools that can describe neurotoxic effects using histological, behavioral and molecular techniques.
The objective of the Safety Neuropharmacology meeting is to bring together experts from a variety of disciplines to review the conventional methods of neurotoxicity assessment, while incorporating new methodology for a current discussion of how best to evaluate neurotoxic effects in pharmaceutical development. Delegates will hear practical presentations on:
DEFINING ICH S7A FOR CNS SAFETY PHARMACOLOGY BEYOND THE FOB
DESIGNING, CONDUCTING, ANALYZING AND INTERPRETING COST-EFFECTIVE CNS SAFETY PHARMACOLOGY STUDY PROGRAMS
ENSURING GLP IN NEUROBEHAVIORAL TESTING
THE EUROPEAN REGULATORY PERSPECTIVE ON CNS SAFETY PHARMACOLOGY SCREENING
THE USE OF AUTOMATED SYSTEMS FOR COMPLEX BEHAVIORAL ANALYSES
EVALUATING THE POTENTIAL FOR DRUG ABUSE OR DEPENDENCE
...among many others from regulatory, academic and industry leaders in the field.
Take advantage of this remarkable opportunity to be part of the first Safety Neuropharmacology meeting! Register early to reserve your spot! Call 800-686-2276 or register online at www.pharmedassociates.com. Please join me in Washington, DC on April 11th & 12th 2005 for this one-of-a-kind meeting.
